New strategies include perhaps patients will be started on several vasopressors with complementary mechanisms of action, patients may be selected for particular vasopressors according to predictive biomarkers, and novel vasopressors may emerge with fewer adverse effects.

 The main purpose of this article is to study the effect of a change in t…[Read more]

The histopathologic studies showed similar results in both groups, showing no signs of structural damage.

Our study did not find evidence of retinal toxicity from a repeated intravitreal injection of PRO-169 or ranibizumab (Lucentis

) in NZW rabbits. These findings support intravitreal PRO-169 as a safe candidate to develop as a future…[Read more]